1
Return

The efficacy and safety comparison between tenofovir and entecavir in treatment of chronic hepatitis B and HBV related cirrhosis: A systematic review and Meta-analysis

delete2017-01-01
delete77
PRE
AI
Y
Ying Han
A
Ajuan Zeng
H
Huiyu Liao
Y
Yanmin Liu
Y
Yuhan Chen
H
Huiguo Ding *
DOI:10.1016/j.intimp.2016.11.022delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
Background: The purpose of this study was to assess the efficacy and safety between tenofovir and entecavir in the treatment of CHB and HBV related cirrhosis through Meta-analysis. Methods The electronic databases of PubMed, the Cochrane Library, Nature, CNKI and WanFang data were searched. The key words were: (tenofovir, entecavir) and (Chronic Hepatitis B or CHB) and Liver cirrhosis. Heterogeneity and report bias were analyzed. Results: There was significant difference of ALT norm level in the short-term period of 3 months (RR = 1.43, 95%CI: 1.06-1.94, P < 0.017) and 6 months (RR = 0.89, 95%CI: 0.81-0.97, P < 0.017), and significant difference of undetectable HBV-DNA only in 3 months follow-up period (RR = 1.59, 95%CI: 1.04-2.42, P < 0.017) between TDF and ETV, but no significant difference in the long-term period. There is significant difference between TDF and ETV in eGFR level (RR = 1.601, 95%CI: 1.035-2.478, P = 0.0034) and hypophosphatemia incidence (RR = 4.008, 95%CI: 1.485-10.820, P = 0.006). Conclusion: TDF has a better efficacy than ETV in 3 months treatment duration, but intriguingly, TDF might not better than ETV during the 6 months treatment period in the viral suppression and liver function improvement. There's no significant difference between TDF and ETV in the long-term treatment duration and in the treatment of HBV related liver cirrhosis. Both TDF and ETV could influence renal function but patients under TDF therapy may have more risk to suffer from renal damage and hypophosphatemia. (C) 2016 Elsevier B.V. All rights reserved.
Keywords:
Chronic hepatitis B
CHB
HBV
Entecavir
Tenofovir
Efficacy
Safety
AI Summary

AI Summary

Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.

Journal

International Immunopharmacology cover
International Immunopharmacology
IF:
4.7
Papers:
1.6W
Citations:
4.1W

Organization

C
Capital Medical University
Scholars:
5.3W
Papers: 3.3W
Citations: 3.2W
Cited Papers

Cited Papers

Citing Papers

Citing Papers